EVAX
Evaxion AS
NASDAQ · Healthcare · Biotechnology · DK
$3.33
+17.67%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.11
From 52W high−53.03%
Volume465685.00
Market cap$30.04M
P/E (TTM)—
P/S (TTM)4.0x
Div yield—
Key dataOct 19, 2026
Open
$3.11
From 52W high
−53.03%
Volume
465685.00
Market cap
$30.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
58.1
MomentumView details →
1D Return
+17.67%
YTD Return
−31.66%
SummaryUpdated Jun 1, 2026
Evaxion Biotech A/S (NASDAQ:EVAX) is a Danish clinical-stage biotechnology company founded in 2008 and headquartered in Hørsholm, Denmark. The company went public on NASDAQ in February 2021. Evaxion specializes in developing artificial intelligence-powered immunotherapies targeting cancers, bacterial diseases, and viral infections. The company has evolved from a traditional biotech firm into an AI-driven immunotherapy platform company, leveraging proprietary machine learning algorithms to identify and develop novel vaccine candidates across multiple therapeutic areas.
Similar companies
Latest newsMore news →